Browse the latest research summaries in the field of pharmacology for spinal cord injury patients and caregivers.
Showing 471-480 of 525 results
Brazilian Journal of Medical and Biological Research, 2017 • January 1, 2017
The study examined the effect of NAC on p-p38 expression and superoxide anion generation (SAG) in the spinal cord of rats with CCI-induced neuropathic pain. CCI led to decreased SFI and increased p-p3...
KEY FINDING: CCI induced a decrease in SFI as well as an increase in p-p38 expression and SAG in the spinal cord.
Ann Rehabil Med, 2015 • October 1, 2015
This retrospective study analyzed urine culture results from 2,629 spinal cord injury (SCI) patients admitted between 2001 and 2013 to determine the prevalence of multidrug-resistant (MDR) organisms a...
KEY FINDING: Significant bacteriuria was identified in 73.4% of urine samples from newly admitted SCI patients, and MDR organisms were isolated in 1.1% of cultures.
Neurotherapeutics, 2022 • May 20, 2022
This study investigates the therapeutic potential of activating BDNF/TrkB signaling and inhibiting δ-secretase in a mouse model of Parkinson's Disease (PD). The researchers used CF3CN, a TrkB agonist...
KEY FINDING: CF3CN activates the TrkB-mediated neurotrophic pathway and decreases α-Syn N103 cleavage, while #11A strongly blocks δ-secretase and reduces α-Syn N103 fragmentation, leading to increased dopaminergic neurons.
Advanced Science, 2023 • November 16, 2022
This study identifies cancer cell lines that are sensitive or resistant to OXPHOS inhibition and reveals that the NNMT-DNMT1 axis plays a critical role in determining cancer cell reliance on mitochond...
KEY FINDING: OXPHOS inhibition-sensitive cancer cells exhibit increased OXPHOS activity and silenced NNMT expression.
J Spinal Cord Med, 2009 • June 1, 2009
This systematic review examined the use of bisphosphonates (BPs) in patients with spinal cord injury (SCI) to prevent bone loss and fractures. The review included six experimental studies and one quas...
KEY FINDING: Bisphosphonates may mildly slow bone density loss after acute SCI at some measurement sites, but this effect isn't always sustained during follow-up.
Medicine, 2014 • December 1, 2014
This study analyzed a large claims database to compare the effectiveness of different oral antibiotics for urinary tract infections (UTIs) in outpatients. The results suggest that norfloxacin and oflo...
KEY FINDING: Norfloxacin had the lowest treatment failure rate compared to TMP-SMX in crude estimate (OR, 0.73; 95% CI, 0.57–0.94), individual covariate adjustment (OR, 0.70; 95% CI, 0.54–0.90), and propensity score matched analysis (OR, 0.73; 95% CI, 0.54–1.00).
Neural Regeneration Research, 2017 • March 1, 2017
This study aimed to elucidate the mechanisms underlying naringin's ability to enhance remyelination after spinal cord injury (SCI) in rats. The findings revealed that naringin treatment mitigated demy...
KEY FINDING: Naringin treatment significantly reduced myelin sheath loss after spinal cord injury, indicating a protective effect on myelin.
Annals of Rehabilitation Medicine, 2011 • October 1, 2011
This study investigated the impact of spinal cord injury (SCI) on colonic contractility and muscarinic receptor subtypes in rats. The researchers aimed to determine how SCI-induced changes in M2 and M...
KEY FINDING: SCI rats showed an increased response to Ach in the proximal colon compared to control rats, indicating altered contractility after SCI.
Neural Regen Res, 2025 • March 1, 2025
Spinal cord injury (SCI) results in permanent neurological disability and poses significant physical, financial, and psychological challenges. The complexity of SCI pathophysiology necessitates explor...
KEY FINDING: The combination of melatonin and dexamethasone showed suitable neuroprotective activities by reducing neutrophil infiltration, cytokine levels, tissue damage, inducible nitric oxide synthase expression, and apoptosis in SCI-treated mice, and motor recovery was also ameliorated.
Asian Journal of Pharmaceutical Sciences, 2023 • August 4, 2023
The study utilized biocompatible mesenchymal stem cell-derived extracellular vesicles as carriers loaded with the CB2 target medicine AM1241 (EVs-AM1241) to protect against neurodegenerative progressi...
KEY FINDING: EVs-AM1241 increased the amount of AM1241 in the brain and improved the biocompatibility of AM1241.